Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C18H25NO.BrH |
| Molecular Weight | 358.346 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Br.[H][C@]12CCCC[C@]13CCN([C@H]2CC4=CC=C(OC([2H])([2H])[2H])C=C34)C([2H])([2H])[2H]
InChI
InChIKey=MISZALMBODQYFT-SPMAXMGUSA-N
InChI=1S/C18H25NO.BrH/c1-19-10-9-18-8-4-3-5-15(18)17(19)11-13-6-7-14(20-2)12-16(13)18;/h6-7,12,15,17H,3-5,8-11H2,1-2H3;1H/t15-,17+,18+;/m1./s1/i1D3,2D3;
Dextromethorphan D6 is a weak uncompetitive antagonist of the NMDA receptor. Dextromethorphan is also acts at nicotinic receptors, sigma-1 rcptor and serotonin and norepinephrine transporters. The incorporation of deuterium serves to reduce dextromethorphan first-pass liver metabolism. AVP-786 is an oral formulation of a combination of deuterated (d6)-dextromethorphan and an ultra-low dose of quinidine. Avanir Pharmaceuticals launched a phase III development program of AVP-786 for the treatment of agitation in patients with Alzheimer's disease.
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
4XS6L3GF4M
Created by
admin on Sat Dec 16 18:15:46 GMT 2023 , Edited by admin on Sat Dec 16 18:15:46 GMT 2023
|
PRIMARY | |||
|
1887258-71-0
Created by
admin on Sat Dec 16 18:15:46 GMT 2023 , Edited by admin on Sat Dec 16 18:15:46 GMT 2023
|
PRIMARY | |||
|
164512974
Created by
admin on Sat Dec 16 18:15:46 GMT 2023 , Edited by admin on Sat Dec 16 18:15:46 GMT 2023
|
PRIMARY | |||
|
100000176368
Created by
admin on Sat Dec 16 18:15:46 GMT 2023 , Edited by admin on Sat Dec 16 18:15:46 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD
